News stories about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a news impact score of 0.06 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.1558687637085 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 26th. BidaskClub lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Barrington Research lowered shares of Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, February 23rd. Sidoti assumed coverage on shares of Anika Therapeutics in a research note on Friday, January 26th. They set a “buy” rating for the company. Finally, First Analysis raised shares of Anika Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $45.00 to $68.00 in a research note on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $62.50.
Shares of NASDAQ:ANIK opened at $45.65 on Friday. The firm has a market cap of $686.06, a price-to-earnings ratio of 23.29, a P/E/G ratio of 2.97 and a beta of 1.73. Anika Therapeutics has a 12-month low of $42.51 and a 12-month high of $69.81.
Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.03). The company had revenue of $29.39 million for the quarter, compared to analyst estimates of $29.85 million. Anika Therapeutics had a net margin of 28.05% and a return on equity of 11.91%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the business earned $0.54 EPS. equities research analysts expect that Anika Therapeutics will post 1.57 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Anika Therapeutics (ANIK) Stock Price” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-anika-therapeutics-anik-stock-price-2.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.